


Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	To Be Assigned 10/713 008
		Filing Date	November 17, 2003
		First Named Inventor	Masaaki IKEDA
		Group Art Unit	To Be Assigned 1636
		Examiner Name	To Be Assigned Tara L. Garvey
Sheet 1 of 2	Attorney Docket Number	64517.000002	

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	U1					
	U2					
	U3					
	U4					
	U5					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>RGH</i>	P1	DAVEY, J. et al., "Identification of the Sequence Responsible for the Nuclear Accumulation of the Influenza Virus Nucleoprotein", <i>Cell</i> (1985), Vol. 40, pp. 667-675.	
<i>RGH</i>	P2	KALDERON, D. et al., "Sequence requirements for nuclear location of simian virus 40 large-T antigen", <i>Nature</i> (1984), Vol. 311, pp. 33-38.	
<i>RGH</i>	P3	KIRSHENBAUM, L. A. et al., "Adenovirus E1A Represses Cardiac Gene Transcription and Reactivates DNA Synthesis in Ventricular Myocytes, via Alternative Pocket Protein- and p300-binding Domains", <i>The Journal of Biological Chemistry</i> (1995), Vol. 270, pp. 7791-7794.	
<i>RGH</i>	P4	KIRSHENBAUM, L.A. et al., "Human E2F-1 Reactivates Cell Cycle Progression in Ventricular Myocytes and Represses Cardiac Gene Transcription", <i>Developmental Biology</i> (1996), Vol. 179, pp. 402-411.	


Examiner Signature	<i>Tara L. Garvey</i>	Date Considered	11/2/05
--------------------	-----------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	To Be Assigned <u>10/713 008</u>
Filing Date	November 17, 2003
First Named Inventor	Masaaki IKEDA
Group Art Unit	To Be Assigned <u>1636</u>
Examiner Name	To Be Assigned <u>Tara L. Garvey</u>
Attorney Docket Number	64517.000002

### NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<u>LLH</u>	P5	LEONE, G. et al., "Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F, <i>Nature</i> (1997), Vol. 387, pp. 422-426.	
<u>LLH</u>	P6	LEW, D. et al., "Isolation of Three Novel Human Cyclins by Rescue of G1 Cyclin (Cin) Function in Yeast", <i>Cell</i> (1991), Vol. 66, pp. 1197-1206.	
<u>LLH</u>	P7	MATSUNSHIME, H. et al., "Colony-Stimulating Factor 1 Regulates Novel Cyclins during the G1 Phase of the Cell Cycle", <i>Cell</i> (1991), Vol. 65, pp. 701-713.	
<u>LLH</u>	P8	MIZUGUCHI, H. et al., "Efficient Construction of a Recombinant Adenovirus Vector by an Improved <i>In Vitro</i> Ligation Method", <i>Human Gene Therapy</i> (1998), Vol. 9, pp. 2577-2583.	
<u>LLH</u>	P9	ROBBINS, J. et al., "Two Interdependent Basic Domains in Nucleoplasmin Nuclear Targeting Sequence: Identification of a Class of Bipartite Nuclear Targeting Sequence", <i>Cell</i> (1991), Vol. 64, pp. 615-623.	
<u>LLH</u>	P10	SCHOLZEN, T. et al., "The Ki-67 Protein: From the Known and the Unknown", <i>Journal of Cell Physiology</i> (2000), Vol. 182, pp. 311-322.	
<u>LLH</u>	P11	SOONPAA, M. H. et al., "Cyclin D1 Overexpression Promotes Cardiomyocyte DNA Synthesis and Multinucleation in Transgenic Mice", <i>J. Clin. Invest.</i> (1997), Vol. 99, pp. 2644-2654.	
<u>LLH</u>	P12	TAMAMORI, M. et al., "Essential roles for G <sub>1</sub> cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy", <i>the American Physiological Society</i> (1998), pp. H2036-2040.	

Examiner Signature	<u>Tara L. Garvey</u>	Date Considered	<u>11/2/05</u>
--------------------	-----------------------	-----------------	----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 64517.000002		SERIAL NO.: 10713.008	
<div style="text-align: center;">  <p>LIST OF MATERIALS CITED BY APPLICANT (Use several sheets if necessary)</p> </div>				INVENTOR'S NAME: IKEDA, et al.		EXAMINER: <del>Not Assigned</del> <i>Tara L. Garvey</i>	
				FILING DATE: November 17, 2003		GROUP ART UNIT: <del>Not Assigned</del> 1636	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	1.						
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	2.						
	3.						
<b>OTHER MATERIALS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<i>LLH</i>	4.	Gavin BROOKS et al., Arresting developments in the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors, Cardiovascular Research (1997), Vol. 39, pp. 301-311					
<i>LLH</i>	5.	Charles J. SHERR et al., CDK inhibitors: positive and negative regulators of G1-phase progression, GENES & DEVELOPMENT, (1999), Vol. 13, pp. 1501-1512					
	6.						
	7.						
	8.						
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						
	16.						
	17.						
	18.						
	19.						
EXAMINER <i>Tara L. Garvey</i>		DATE CONSIDERED <i>11/2/05</i>					
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							